May 4, 2024
CellCarta’s poster on M-Protein analysis in plasma of multiple myeloma (MM) patients highlights the use of intact mass spectrometry for monitoring disease progression. This non-invasive method, requiring only a small volume of plasma or serum, measures M-Protein levels with high sensitivity, precision, and reproducibility.
The study demonstrated that mass spectrometry could detect significant reductions in M-Protein concentration, providing an effective alternative to bone marrow biopsies for evaluating treatment response and measurable residual disease (MRD). The workflow supports high-frequency sampling, offering a comprehensive profile of disease progression and treatment efficacy in MM patients.
View the poster
M-Protein Analysis in Plasma of Multiple Myeloma Patients by Intact Mass Spectrometry
Press Releases
September 24, 2025
More infoCellTalk Blog
September 19, 2025
Flow Cytometry
More infoCellTalk Blog
August 12, 2025
More info